News for Medivir AB (MVR.MU)

/PRNewswire/ -- Promising clinical results, successful business development and secured financing October - December Financial summary for the quarter Net...

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has ch...

AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for ...

Medivir AB (MVIR)announces that it has entered into a license agreement with Ubiquigent for the company's preclinical USP7 research program.Under the terms of the agreement, Medivir...

HUDDINGE, Sweden, Feb. 7, 2021 /PRNewswire/ -- The Board of Directors in Medivir AB has decided to summon an extraordinary general meeting on 11 March 2021 to propose a directed issue to the...

HUDDINGE, Sweden, Feb. 7, 2021 /PRNewswire/ -- The Board of Directors in Medivir AB (publ) ('Medivir' or the 'Company') has decided to summon an e...

/PRNewswire/ -- The Board of Directors in Medivir AB (publ) ("Medivir" or the "Company") has decided to summon an extraordinary general meeting on 11 March...

HUDDINGE, Sweden, Feb. 7, 2021 /PRNewswire/ -- The Board of Directors in Medivir AB (publ) ("Medivir" or the "Company") has decided to ...

STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that a presentation entitled 'Phase I study of the no...

/PRNewswire/ -- Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM...